摘要
目的探讨对甲状腺功能亢进采用放射性核素^(131)I治疗的效果以及安全性。方法选择单县中心医院2019年1月至2020年6月诊治甲状腺功能亢进患者70例,按照治疗方案不同分为常规采用丙硫氧嘧啶治疗的对照组(n=35)与联合使用放射性核素^(131)I治疗的试验组(n=35),对比两组临床疗效、治疗前后血清游离三碘甲状腺原氨酸(FT_(3))、血清游离甲状腺素(FT_(4))、促甲状腺激素(TSH)水平及不良反应。结果试验组治疗总有效率高于对照组,差异有统计学意义(P<0.05)。试验组治疗后FT_(3)、FT_(4)水平低于对照组,差异有统计学意义(P<0.05);TSH水平高于对照组,差异有统计学意义(P<0.05)。两组不良反应发生率比较差异无统计学意义(P>0.05)。结论对甲状腺功能亢进在常规治疗的基础上联用放射性核素^(131)I治疗可提高治疗效果,能够降低FT_(3)、FT_(4)水平,提高TSH水平,不会导致不良反应明显增加,值得推广。
Objective To investigate the efficacy and safety of radionuclide ^(131)I in the treatment of hyperthyroidism.Methods A total of 70 patients with hyperthyroidism admitted to our hospital from January 2019 to June 2020 were selected and divided into the control group(n=35)and the experimental group(n=35)according to different treatment schemes.The control group was treated with conventional propylthiouracil,while the experimental group was treated with propylthiouracil combined with radionuclide 131 The clinical efficacy,adverse reactions(ADRs)after treatment and level differences of serum free triiodothyronine(FT_(3)),serum free thyroxine(FT4)and thyroid-stimulating hormone(TSH)were compared before and after treatment.Results The total efficacy rate of the experimental group was higher than that of the control group,with statistically significant difference(P<0.05).After treatment,the levels of FT_(3) and FT4 in the experimental group were lower than those in the control group,with statistically significant differences(P<0.05).TSH level of the experimental group was higher than that of the control group,with statistically significant difference(P<0.05).There was no statistically significant difference in the incidence of ADRs between the experimental group and the control group(P>0.05).Conclusion Combined treatment of hyperthyroidism with radionuclide ^(131)I on the basis of conventional treatment can improve the therapeutic efficacy,reduce FT_(3) and FT4 levels,and improve TSH levels,without causing obvious increase of ADRs,which is worthy of promotion.
作者
孙东兵
SUN Dongbing(Department of Nuclear Medicine,Shanxian Central Hospital,Shandong,Shanxian 274300,China)
出处
《中国医药科学》
2021年第7期228-230,共3页
China Medicine And Pharmacy
